

RECEIVED  
MAY 23 2002  
TECHNICAL CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
955-16

SERIAL NO.  
10/076,204

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Levi, et al.

CONFIRMATION NO.  
8595

(Use several sheets if necessary)

FILING DATE  
February 13, 2002

GROUP  
1614



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	WO/00/20011	4/13/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1.	B Malinowska, et al., "Histamine H <sub>3</sub> Receptors - General Characterization and Their Function in the Cardiovascular System", <i>Journal of Physiology and Pharmacology</i> , 1998. 49(2):191-211.
	2.	H. van der Goot, et al., "Isothiourea Analogues of Histamine as Potent Agonists or Antagonists of the Histamine H <sub>3</sub> -Receptor" <i>Eur. J. Med. Chem.</i> 1992. 27: 511-517.
	3.	Iwan J.P. De Esch, et al., "Characterization of the Binding Site of the Histamine H <sub>3</sub> Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl) cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopropylamine", <i>Journal of Medicinal Chemistry</i> , 1999. 42(7): 1115-1122.
	4.	Christina J. Mackins, et al., "Therapeutic Potential of H <sub>3</sub> -receptor Agonists in Myocardial Infarction", <i>Exp. Opin. Invest Drugs</i> 2000. 9(11): 2537-2542.
	5.	Catherine Mazenot, et al., "Histamine H <sub>3</sub> -receptor Stimulation is Unable to Modulate Noradrenaline Release by the Isolated Rat Heart During Ischaemia-Reperfusion", <i>Fundam. Clin. Pharmacol.</i> 1999. 13(4): 455-60.
	6.	Catherine Mazenot, et al., "In vivo Demonstration of H <sub>3</sub> -histaminergic Inhibition of Cardiac Sympathetic Stimulation by R- $\alpha$ -methyl-histamine and its Prodrug BP 2.94 in the Dog", <i>British Journal of Pharmacology</i> 1999. 126: 264-268.
	7.	Pierre Theroux, M.D., "Myocardial Cell Protection. A Challenging Time for Action and Challenging Time of Clinical Research", <i>Circulation</i> 2000. 101:2874-2876.

EXAMINER

DATE CONSIDERED

8/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
955-16

SERIAL NO.  
10/076,204

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Levi, et al.

CONFIRMATION NO.  
8595

(Use several sheets if necessary)

FILING DATE  
February 13, 2002

GROUP  
1614



TECH CENTER 1600/2900

MAY 23 2002

RECEIVED

- |     |  |
|-----|--|
| 8.  | Hans-Jurgen Rupprecht, M.D., et al., "Cardioprotective Effects of the Na <sup>+</sup> /H <sup>+</sup> Exchange Inhibitor Cariporide in Patients with Acute Anterior Myocardial Infarction Undergoing Direct PTCA", <i>Circulation</i> 2000. 101:2902-2908.   |
| 9.  | Morris Karmazyn, et al., "The Myocardial Na <sup>+</sup> -H <sup>+</sup> Exchange. Structure, Regulation and Its Role in Heart Disease", <i>Circulation Research</i> 1999. 85:777-786.   |
| 10. | Eiichiro Hatta, et al., "Activation of Histamine H <sub>3</sub> Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia", <i>Journal of Pharmacology and Experimental Therapeutics</i> 1997. 283:494-500.  |
| 11. | Randi B. Silver, et al., "Coupling of Histamine H <sub>3</sub> Receptors to Neuronal Na <sup>+</sup> /H <sup>+</sup> Exchange: A Protective Mechanism in Myocardial Ischemia", <i>PNAS Early Edition</i> 2001. 1-5.  |
| 12. | Rob Leurs, et al., "Therapeutic Potential of Histamine H <sub>3</sub> Receptor Agonists and Antagonists", <i>Trends in Pharmacological Sciences</i> 1998. 19:177-183.  |
| 13. | P.K. Rangachari, "The Fate of Released Histamine: Reception, Response and Termination", <i>Yale Journal of Biology and Medicine</i> 1998. 71:173-182.  |
| 14. | Randi B. Silver, et al., "Coupling of Histamine H <sub>3</sub> receptors to Neuronal Na <sup>+</sup> /H <sup>+</sup> Exchange: A Novel Protective Mechanism in Myocardial Ischemia", <i>PNAS</i> 2001. 98(5):2855-2859.  |
| 15. | Michiaki Imamura, et al., "Activation of Histamine H <sub>3</sub> -Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia", <i>Circ. Res.</i> 1996. 78:475-481.  |
| 16. | Roberto Levi, et al., "Histamine H <sub>3</sub> -Receptors: A New Frontier in Myocardial Ischemia", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 2000. 292:825-830.  |
| 17. | H.D. Holtje, et al., "Molecular Modelling Studies on Histamine H <sub>2</sub> - and H <sub>3</sub> -Receptor Agonists", <a href="http://www.pharm.uni-duesseldorf.de/forschung/mitarbeiter/sippl/Maastricht.pdf">www.pharm.uni-duesseldorf.de/forschung/mitarbeiter/sippl/Maastricht.pdf</a> . 1-12. No date available |

EXAMINER

DATE CONSIDERED

8/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
955-16

SERIAL NO.  
10/076,204

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT


(Use several sheets if necessary)

APPLICANT  
Levi, et al.

CONFIRMATION NO.  
8595

FILING DATE  
February 13, 2002

GROUP  
1614




- |     |   |
|-----|---|
| 18. | Patrizio Blandina, "The Role of Interactions Between Histaminergic and Cholinergic Systems in Learning and Memory",<br><a href="http://www.mcmaster.ca/inabis98/huston/blandina0227/two.html">www.mcmaster.ca/inabis98/huston/blandina0227/two.html</a> . (No date available) |
| 19. | Rob Leurs, et al., "Histamine Receptors", <i>Tocris Cookson</i> .<br><a href="http://www.biotrend.com/pdf/histamine.pdf">www.biotrend.com/pdf/histamine.pdf</a> . 1-6. (No date available)  |

RECEIVED  
MAY 23 2002  
TECH CENTER 1600/2900  
154403

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO. 955-16	SERIAL NO. 10/076,204
	APPLICANT Levi, et al.	CONFIRMATION NO. 8595
	FILING DATE February 13, 2002	GROUP 1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Akagi, et al., "Role of histamine H <sub>3</sub> receptor on hypoxia-reoxygenation-induced cardiac dysfunction in guinea pigs", PubMed No. 8750792, <i>Methods Find Exp. Clin. Pharmacol.</i> , 1995, Vol. 17 Suppl C:30-35. (abstract only).
		2.	Imamura, Michiaki, et al., "Histamine H <sub>3</sub> -Receptor-Mediated Inhibition of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers", <i>Circulation Research</i> 1996, 78(5):863-869.
		3.	Luo, Xiao-Xing, et al., "Histamine H <sub>3</sub> -receptors inhibit sympathetic neurotransmission in guinea pig myocardium", <i>European Journal of Pharmacology</i> 1991, 204:311-314.

171032\_1

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

EXAMINER



DATE CONSIDERED

8/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.